- Home
- ALDX vs PRQR Comparison
ALDX vs PRQR Comparison
Compare ALDX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- PRQR
- Stock Information
- Founded
- ALDX 2004
- PRQR 2012
- Country
- ALDX United States
- PRQR Netherlands
- Employees
- ALDX N/A
- PRQR N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- PRQR Health Care
- Exchange
- ALDX Nasdaq
- PRQR Nasdaq
- Market Cap
- ALDX 304.9M
- PRQR 309.5M
- IPO Year
- ALDX 2014
- PRQR 2014
- Fundamental
- Price
- ALDX $6.58
- PRQR $1.65
- Analyst Decision
- ALDX Strong Buy
- PRQR Strong Buy
- Analyst Count
- ALDX 2
- PRQR 6
- Target Price
- ALDX $10.00
- PRQR $8.50
- AVG Volume (30 Days)
- ALDX 666.8K
- PRQR 448.8K
- Earning Date
- ALDX 05-01-2025
- PRQR 03-13-2025
- Dividend Yield
- ALDX N/A
- PRQR N/A
- EPS Growth
- ALDX N/A
- PRQR N/A
- EPS
- ALDX N/A
- PRQR N/A
- Revenue
- ALDX N/A
- PRQR $20,235,014.00
- Revenue This Year
- ALDX N/A
- PRQR $39.44
- Revenue Next Year
- ALDX N/A
- PRQR N/A
- P/E Ratio
- ALDX N/A
- PRQR N/A
- Revenue Growth
- ALDX N/A
- PRQR 196.41
- 52 Week Low
- ALDX $2.75
- PRQR $1.59
- 52 Week High
- ALDX $7.20
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ALDX 53.63
- PRQR 28.26
- Support Level
- ALDX $6.22
- PRQR $1.78
- Resistance Level
- ALDX $6.87
- PRQR $1.87
- Average True Range (ATR)
- ALDX 0.46
- PRQR 0.11
- MACD
- ALDX -0.03
- PRQR -0.02
- Stochastic Oscillator
- ALDX 60.51
- PRQR 10.53
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.